Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Assets: 2017-2024

Historic Other Non-Current Assets for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $73.0 million.

  • Arcus Biosciences' Other Non-Current Assets fell 13.33% to $65.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 13.33%. This contributed to the annual value of $73.0 million for FY2024, which is 31.13% down from last year.
  • As of FY2024, Arcus Biosciences' Other Non-Current Assets stood at $73.0 million, which was down 31.13% from $106.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Other Non-Current Assets ranged from a high of $116.0 million in FY2021 and a low of $6.2 million during FY2020.
  • Its 3-year average for Other Non-Current Assets is $97.7 million, with a median of $106.0 million in 2023.
  • In the last 5 years, Arcus Biosciences' Other Non-Current Assets skyrocketed by 1,757.19% in 2021 and then slumped by 31.13% in 2024.
  • Arcus Biosciences' Other Non-Current Assets (Yearly) stood at $6.2 million in 2020, then skyrocketed by 1,757.19% to $116.0 million in 2021, then declined by 1.72% to $114.0 million in 2022, then declined by 7.02% to $106.0 million in 2023, then slumped by 31.13% to $73.0 million in 2024.